drugset / Trial / NCT04152629
Real World Evidence of the Efficacy and Safety of FOQUEST
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a four-month, phase IV, open-label study of ADHD symptomatology and functional outcomes in pediatric (6 to 17 years old) and adult (≥18 years or older) patients with ADHD treated with FOQUEST or VYVANSE.
Timeline
- Start
- 2019-09-19
- Primary completion
- 2021-07-09
- Completion
- 2021-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lisdexamfetamine Dimesylate | Small molecule | 10 mg | — |
| Comparator | Lisdexamfetamine Dimesylate | Small molecule | 20 mg | — |
| Comparator | Lisdexamfetamine Dimesylate | Small molecule | 30 mg | — |
| Comparator | Lisdexamfetamine Dimesylate | Small molecule | 40 mg | — |
| Comparator | Lisdexamfetamine Dimesylate | Small molecule | 50 mg | — |
| Comparator | Lisdexamfetamine Dimesylate | Small molecule | 60 mg | — |
| Subject | Methylphenidate | Small molecule | 25 mg | — |
| Subject | Methylphenidate | Small molecule | 35 mg | — |
| Subject | Methylphenidate | Small molecule | 45 mg | — |
| Subject | Methylphenidate | Small molecule | 55 mg | — |
| Subject | Methylphenidate | Small molecule | 70 mg | — |
| Subject | Methylphenidate | Small molecule | 85 mg | — |
| Subject | Methylphenidate | Small molecule | 100 mg | — |